Article Text

AB0383 Relationship of RA disease activity classifications and medication usage with ethnicity
  1. G. Kerr1,2,3,
  2. Y. Yazici4,
  3. Y. Sherrer5,
  4. R. Nair6,
  5. E. Treadwell7,
  6. A. Mosley-Williams8,9,
  7. L. Espinoza10,
  8. I. Garcia-Valladares10,
  9. A. Ince11,
  10. J. Huang3,
  11. C. Nunziato3,
  12. W.A. McCracken4,
  13. C. Swearingen4
  1. 1Georgetown University
  2. 2VA Medical Center
  3. 3Howard University, Washington, DC
  4. 4New York University, New York, NY
  5. 5Centre for Rheumatology, Immunology and Arthritis, Fort Lauderdale, FL
  6. 6Washington Hospital Center, Washington, DC
  7. 7East Carolina University, Greenville, NC
  8. 8VA Medical Center
  9. 9Wayne State University, Detroit, MI
  10. 10Louisiana State University, Baton Rouge, LA
  11. 11St Louis University, St Louis, MO, United States


Background Advances in treatment for RA and focus on “treating to target” has led to increased use of disease activity measures in routine care. Little data exists regarding disease activity in ethnic minorities. The Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) is a registry comprise of RA clinical measures obtained during routine care.

Objectives To evaluate RA disease activity levels and use of DMARDs and biologic agents in ethnic minorities.

Methods RA patients of self-reported ethnicity from 9 US sites are enrolled. Demographics, comorbidities, treatments, disease activity composite scores (RAPID3, CDAI, and DAS289) were collected. Analyses of differences in clinical variables in racial groups was performed using Kruskal-Wallis for continuous variables and exact tests for qualitative variables; post-hoc pairwise comparisons between racial groups were made with the Wilcoxon rank sum test and adjusted using the Bonferonni correction (p<0.008 for significance).

Results 502 RA patients were enrolled (Table). For the RAPID3, DAS28, and CDAI there were not any significant racial differences between categories. Differences between races existed in medications, classified as neither DMARD or biologic, DMARD only, biologic only, and both DMARD and biologic medications. African-Americans had a smaller percentage of patients than Caucasians or Hispanics for biologic use and were more likely to be on DMARDs only rather than combination treatments.

Conclusions Although differences exist in RA treatments amongst ethnic groups, current RA composite disease activity scores appear to be similar. Further analysis is needed to evaluate these findings.

Disclosure of Interest G. Kerr Grant/Research support from: Genentech and Biogen IDEC, Inc, Y. Yazici Grant/Research support from: Abbott, BMS, Centocor, Genentech, Consultant for: Abbott, BMS, Genentech, Celgene, UCB, Y. Sherrer Grant/Research support from: AstraZeneca, Mercke, UCB, Sanofi Adventis, Celgene, Lily, Roche, Amgen, Wyeth, Pfizer, Novartis, Speakers Bureau: AstraZeneca, Human Genome Science, Amgen, Pfizer, Wyeth, R. Nair: None Declared, E. Treadwell: None Declared, A. Mosley-Williams: None Declared, L. Espinoza: None Declared, I. Garcia-Valladares: None Declared, A. Ince: None Declared, J. Huang: None Declared, C. Nunziato: None Declared, W. McCracken: None Declared, C. Swearingen: None Declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.